W

Wave Life Sciences USA

Clinical-stage biotech developing stereopure oligonucleotides

Scientist 2 - Bioanalytical and Biomarker Development

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeLexington, MA, USAIn-person

About the Job

Requirements

  • A B.S. or M.S. degree and at least 8 years of relevant industry experience.
  • Hands-on experience in bioanalytical and biomarker assay development and qualification using methods such as ELISA, MSD, LC-MS, RT-PCR, qPCR, and cell-based assays to support discovery, preclinical, and potential clinical projects.
  • Experience transferring assays to contract research organizations (CROs), or prior experience within bioanalytical CROs, and troubleshooting technical issues.
  • Ability to independently analyze data and present and share it with stakeholders.
  • Familiarity with writing standard operating procedures (SOPs) and other technical reports as needed.
  • Experience within a start-up or small biotechnology environment.

Responsibilities

  • Perform method development and qualification for oligonucleotides in biological matrices using LC-MS/MS, MSD, and/or ELISA-based assays.
  • Perform sample analysis according to established method protocols in different biological matrices, such as blood, plasma, and tissue.
  • Participate in planning experimental design and executing all aspects of bioanalysis, including efficient assay development to support investigative toxicology and pharmacokinetic (PK) studies.
  • Transfer methods to CROs and manage their work.
  • Prepare clear and accurate reports for internal and external projects.
  • Prepare clearly articulated experimental reports and data presentations.

About the Company

Wave Life Sciences USA

Clinical-stage biotech developing stereopure oligonucleotides

Wave Life Sciences develops stereopure nucleic acid therapies for genetically defined diseases. Its PRISM platform designs stereopure oligonucleotides that enable RNA interference, antisense silencing, splicing modulation, and RNA editing, including AIMers that recruit ADAR enzymes to edit RNA without changing the DNA. The company funds R&D mainly through partnerships and licensing (notably with GSK) and has programs in conditions like Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity. Its goal is to bring approved RNA medicines to patients by advancing a diversified pipeline and sustaining long-term collaborations that fund development.

Company size
201-500
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2012

Recently Posted Jobs

Explore more opportunities at Wave Life Sciences USA

See more jobs